Invesco Pharmaceuticals ETF

PJP

Market cap $349M

Invesco Pharmaceuticals ETF offers a higher dividend yield and lower five-year beta than State Street SPDR S&P Biotech ETF State Street SPDR S&P Biotech ETF holds 155 securities compared to 30 in Invesco Pharmaceuticals ETF Invesco Pharmaceuticals ETF has experienced a significantly smaller max drawdown of 17.5% over the last five years, compared to 54% for State Street SPDR S&P Biotech ETF

Invesco Pharmaceuticals ETF has a higher 5-year growth total of $1,563 compared to $1,480 for First Trust NYSE Arca Biotechnology Index Fund First Trust NYSE Arca Biotechnology Index Fund is more affordable with a 0.55% expense ratio while Invesco Pharmaceuticals ETF charges 0.57% Invesco Pharmaceuticals ETF experienced a lower 5-year maximum drawdown of 17.50% compared to 29.90% for the First Trust fund

The iShares U.S. Pharmaceuticals ETF (IHE) charges a lower expense ratio and pays a higher dividend than the Invesco Pharmaceuticals ETF (PJP). IHE is heavily concentrated in its two largest holdings, while PJP spreads its bets more evenly across the sector's biggest names.

The VanEck Pharmaceutical ETF provides a lower expense ratio and a more substantial dividend yield than the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF delivered higher 1-year total returns but has lagged the VanEck fund over a 5-year horizon.

State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio and far greater assets under management than Invesco Pharmaceuticals ETF. Invesco's ETF focuses exclusively on 29 pharmaceutical companies, whereas the SPDR fund provides broader exposure across the healthcare sector.

Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and higher dosing—effectively extends product lifecycles and drives shareholder value.

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on June 23, 2005.

Invesco Pharmaceuticals ETF provides concentrated exposure to 29 drug manufacturers, while Invesco S&P 500 Equal Weight Health Care ETF offers equal-weighted access to 59 healthcare stocks Invesco S&P 500 Equal Weight Health Care ETF is more cost-efficient with a 0.40% expense ratio compared to 0.57% for Invesco Pharmaceuticals ETF Invesco Pharmaceuticals ETF has achieved higher total returns over both 1-year and 5-year periods with lower overall price volatility as measured by beta

The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.